Literature DB >> 14556779

Receptor tyrosine kinases in normal and malignant haematopoiesis.

John T Reilly1.   

Abstract

Haematopoiesis is controlled by a number of growth factors and cytokines, a number of which act through binding to high-affinity receptor tyrosine kinases (RTKs). Approximately 20 different RTK classes have been identified, all of which share a similar structure that includes a ligand binding extracellular domain, a single transmembrane domain and an intracellular tyrosine kinase domain. Recent studies have linked an increasing number of mutations in the RTKs to the pathogenesis of both acute and chronic leukaemia. For example, the FLT3 receptor, a RTK class III, is the most commonly mutated gene in acute myeloid leukaemia, while c-kit mutations are strongly linked to the development of mast cell malignancy. This review summarizes the RTK classes that are known to be expressed on normal haematopoietic tissue and highlights the many 'gain-of-function' mutations involved in leukaemogenesis. It is to be hoped that this knowledge will provide important new insights for targeted therapy in leukaemia.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14556779     DOI: 10.1016/s0268-960x(03)00024-9

Source DB:  PubMed          Journal:  Blood Rev        ISSN: 0268-960X            Impact factor:   8.250


  17 in total

1.  Heterozygous kit mutants with little or no apparent anemia exhibit large defects in overall hematopoietic stem cell function.

Authors:  Yashoda Sharma; Clinton M Astle; David E Harrison
Journal:  Exp Hematol       Date:  2007-02       Impact factor: 3.084

2.  Structural basis for stem cell factor-KIT signaling and activation of class III receptor tyrosine kinases.

Authors:  Heli Liu; Xiaoyan Chen; Pamela J Focia; Xiaolin He
Journal:  EMBO J       Date:  2007-01-25       Impact factor: 11.598

Review 3.  Extrinsic and intrinsic regulation of early natural killer cell development.

Authors:  Markus D Boos; Kevin Ramirez; Barbara L Kee
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

4.  Persistence of leukemia-initiating cells in a conditional knockin model of an imatinib-responsive myeloproliferative disorder.

Authors:  Katherine I Oravecz-Wilson; Steven T Philips; Omer H Yilmaz; Heather M Ames; Lina Li; Brendan D Crawford; Alice M Gauvin; Peter C Lucas; Kajal Sitwala; James R Downing; Sean J Morrison; Theodora S Ross
Journal:  Cancer Cell       Date:  2009-08-04       Impact factor: 31.743

Review 5.  JAK2 V617F in myeloid disorders: molecular diagnostic techniques and their clinical utility: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology.

Authors:  David P Steensma
Journal:  J Mol Diagn       Date:  2006-09       Impact factor: 5.568

Review 6.  Integration of hypoxic HIF-α signaling in blood cancers.

Authors:  L Schito; S Rey; M Konopleva
Journal:  Oncogene       Date:  2017-05-22       Impact factor: 9.867

7.  Ras in cancer and developmental diseases.

Authors:  Alberto Fernández-Medarde; Eugenio Santos
Journal:  Genes Cancer       Date:  2011-03

8.  Leukemic transformation in mice expressing a NUP98-HOXD13 transgene is accompanied by spontaneous mutations in Nras, Kras, and Cbl.

Authors:  Christopher Slape; Leah Y Liu; Sarah Beachy; Peter D Aplan
Journal:  Blood       Date:  2008-06-19       Impact factor: 22.113

9.  Translational research in complex etiopathogenesis and therapy of hematological malignancies: the specific role of tyrosine kinases signaling and inhibition.

Authors:  Karmen Stankov; Suncica Stankov; Stevan Popović
Journal:  Med Oncol       Date:  2008-12-03       Impact factor: 3.064

10.  Quantitative assay for the detection of the V617F variant in the Janus kinase 2 (JAK2) gene using the Luminex xMAP technology.

Authors:  François W Paradis; Raynald Simard; Daniel Gaudet
Journal:  BMC Med Genet       Date:  2010-04-01       Impact factor: 2.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.